Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish overall survival data on afatinib vs gefitinib in patients with EGFR mutation–positive non–small cell lung cancer. (Abstract LBA43)
Sumanta K. Pal, MD, of the City of Hope, discusses phase II findings on the efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer who have received prior treatment. Follow him on Twitter: @montypal
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the importance of tumor location, and its implications for treatment, in right-sided and left-sided metastatic colon cancer.
Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on cabozantinib vs sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor and intermediate risk. (Abstract LBA30) Follow him on Twitter: @DrChoueiri
Susana N. Banerjee, PhD, MBBS, of The Royal Marsden NHS Foundation Trust, discusses phase II findings on abiraterone in patients with recurrent epithelial ovarian cancer. (Abstract LBA33)
